Read Our Recent News
NanoMab Publishes Clinical Research Paper on Journal of Nuclear Medicine
Date: Feb 22nd, 2019 NanoMab Publishes Clinical Research Paper on Journal of Nuclear Medicine Shanghai, China, February 22nd, 2019. NanoMab published its FIH data for the first 16 patients of 99mTc-NM-01 on Journal of Nuclear Medicine (JNM), titled ‘Early phase I study of a 99mTc labeled anti-PD-L1 single domain antibody in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer’. 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression [...]
NanoMab Enters into Agreement with Guy’s and St Thomas’ NHS Foundation Trust for Investigator Initiated Study
Date: Feb 7th, 2019 NanoMab Enters into Agreement with Guy’s and St Thomas’ NHS Foundation Trust for Investigator Initiated Study London, UK, February 7th, 2019. NanoMab announced a collaboration with Guy’s and St Thomas’ NHS Foundation Trust on the investigator-initiated study for 99mTc-NM-01. The primary objective is to assess the change in PD-L1 expression in relation to immunotherapy in NSCLC and melanoma patients. 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression [...]
NanoMab and King’s College London to Collaborate on Next Generation One Step Radiolabelling
Date: Sep 12th, 2018 NanoMab and King’s College London to Collaborate on Next Generation One Step Radiolabelling Shanghai, China, September 12th, 2018. NanoMab announced a collaboration with the School of Biomedical Engineering and Imaging Sciences, King’s College London for the development of next generation single step radiolabelling for 99mTc/188Re.
NanoMab and LifeArc to Collaborate on Camelid Single Domain Antibody Humanization
Date: Aug 2nd, 2018 NanoMab and LifeArc to Collaborate on Camelid Single Domain Antibody Humanization Shanghai, China, August 2nd, 2018. NanoMab announced a collaboration with LifeArc (previously known as MRCT) for the humanization of camelid single domain antibody NM-02.
NanoMab Announces First NSCLC Patient Dosed in FIH of 99mTc-NM-01
Date: March 30th, 2018 NanoMab Announces First NSCLC Patient Dosed in FIH of 99mTc-NM-01 Shanghai, China, March 30th, 2018. NanoMab today announced dosing of the first patients for its FIH of 99mTc-NM-01 in patients with non-small cell lung cancer at SGH. 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression in patients before or during immuno-oncology treatment.
NanoMab To Initiate FIH for 99mTc-NM-01 at SGH
Date: Feb 27th, 2018 NanoMab To Initiate FIH for 99mTc-NM-01 at SGH Shanghai, China, February 27th, 2018. NanoMab announced that it has decided to initiate FIH with NM-01, which is the company’s non-small cell lung cancer (NSCLC) program. The kick off meeting was held at Shanghai General Hospital (SGH). The primary objective of this study is to evaluate safety, tolerability and pharmacokinetics of NM-01. 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 [...]